Insulin-like growth factor-I regulation of immune function: A potential therapeutic target in autoimmune diseases?

Pharmacological Reviews

Volumn 62, Issue 2, 2010, Pages 199-236

  Smith, Terry J ^a,b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; 3 [3 (4 METHYL PIPERAZIN L YL)CYCLOBUTYL] 1 (2 PHENYLQUINOLIN 7 YL)IMIDAZO[1,5 ALPHA]PYRAZIN 8 YLAMINE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; AVE 1642; BIIB 022; BMS 5369234; BMS 536924; CIXUTUMUMAB; CP 751871; DOXORUBICIN; EM 164; FLUOROURACIL; IMCA 12; MONOCLONAL ANTIBODY; NVP TAE 226; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; CONNECTIVE TISSUE DISEASE; CROHN DISEASE; DEMYELINATION; DIABETES MELLITUS; GRAVES DISEASE; HEMATOPOIESIS; HUMAN; HYPERGLYCEMIA; IMMUNE FUNCTION TEST; LUNG CANCER; MACROPHAGE; MONOCYTE; MYELOMA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THYMUS;

AUTOIMMUNE DISEASES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; RECEPTOR, IGF TYPE 1;

EID: 77952349493     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.109.002469     Document Type: Review

References (401)

1. Abroun S, Ishikawa H, Tsuyama N, Liu S, Li FJ, Otsuyama K, Zheng X, Obata M, and Kawano MM (2004) Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor α [published erratum appears in Blood 103:2891, 2004]. Blood 103:2291-2298.
2. Adams TE, Epa VC, Garrett TP, and Ward CW (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093.
3. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, and Shlomchik MJ (2007) Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179:3351-3361.
4. Alpdogan O, Muriglan SJ, Kappel BJ, Doubrovina E, Schmaltz C, Schiro R, Eng JM, Greenberg AS, Willis LM, Rotolo JA, et al. (2003) Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation 75:1977-1983.
5. Ambrosini G, Adida C, and Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
6. Andress DL (1995) Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem 270:28289-28296.
7. Arkins S, Rebeiz N, Biragyn A, Reese DL, and Kelley KW (1993) Murine macrophages express abundant insulin-like growth factor-I class I Ea and Eb transcripts. Endocrinology 133:2334-2343.
8. Arkins S, Rebeiz N, Brunke-Reese DL, Biragyn A, and Kelley KW (1995a) Interferon-γ inhibits macrophage insulin-like growth factor-I synthesis at the transcriptional level. Mol Endocrinol 9:350-360.
9. Arkins S, Rebeiz N, Brunke-Reese DL, Minshall C, and Kelley KW (1995b) The colony-stimulating factors induce expression of insulin-like growth factor-I messenger ribonucleic acid during hematopoiesis. Endocrinology 136:1153-1160.
10. Bagley CJ, May BL, Szabo L, McNamara PJ, Ross M, Francis GL, Ballard FJ, and Wallace JC (1989) A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochem J 259:665-671.
11. Baker G, Mazziotti G, von Ruhland C, and Ludgate M (2005) Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy. Endocrinology 146:835-844.
12. Ban Y and Tomer Y (2005) Susceptibility genes in thyroid autoimmunity. Clin Dev Immunol 12:47-58.
13. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP Jr., and Roth RA (1999) Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 274:20281-20286.
14. Baserga R, Peruzzi F, and Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107:873-877.
15. Baudler S, Baumgartl J, Hampel B, Buch T, Waisman A, Snapper CM, Krone W, and Brüning JC (2005) Insulin-like growth factor-1 controls type 2 T cell-independent B cell response. J Immunol 174:5516-5525.
16. Baxter RC (1993) IGF binding protein-3 and the acid-labile subunit: formation of the ternary complex in vitro and in vivo. Adv Exp Med Biol 343:237-244.
17. Baxter RC and Firth SM (1995) Modulation of human IGF binding protein-3 activity by structural modification. Prog Growth Factor Res 6:215-222.
18. Bayne ML, Applebaum J, Underwood D, Chicchi GG, Green BG, Hayes NS, and Cascieri MA (1989) The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. J Biol Chem 264:11004-11008. (Pubitemid 19168823)
19. Beattie RM, Camacho-Hübner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, and Savage MO (1998) Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 49:483-489.
20. Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ, and Sorisky A (2000) Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol 279:C335-C340.
21. Benmerah A, Lamaze C, Bègue B, Schmid SL, Dautry-Varsat A, and Cerf-Bensussan N (1998) AP-2/Eps15 interaction is required for receptor-mediated endocytosis. J Cell Biol 140:1055-1062.
22. Berfield AK, Andress DL, and Abrass CK (2000) IGFBP-5(201-218) stimulates Cdc42GAP aggregation and filopodia formationin migrating mesangial cells. Kidney Int 57:1991-2003.
23. Bergerot I, Fabien N, Maguer V, and Thivolet C (1995) Insulin-like growth factor-1 (IGF-1) protects NOD mice from insulitis and diabetes. Clin Exp Immunol 102:335-340.
24. Berman JS and Center DM (1987) Chemotactic activity of porcine insulin for human T lymphocytes in vitro. J Immunol 138:2100-2103.
25. Bernabei P, Bosticardo M, Losana G, Regis G, Di Paola F, De Angelis S, Giovarelli M, and Novelli F (2003) IGF-1 down-regulates IFN-γR2 chain surface expression and desensitizes IFN-γ/STAT-1 signaling in human T lymphocytes. Blood 102:2933-2939.
26. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, and McCubrey JA (2006) Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 20:1254-1260.
27. Beschorner WE, Divic J, Pulido H, Yao X, Kenworthy P, and Bruce G (1991) Enhancement of thymic recovery after cyclosporine by recombinant human growth hormone and insulin-like growth factor-I. Transplantation 52:879-884.
28. Bhaumick B and Bala RM (1987) Binding and degradation of insulin-like growth factors I and II by rat kidney membrane. Endocrinology 120:1439-1448.
29. Binz K, Joller P, Froesch P, Binz H, Zapf J, and Froesch ER (1990) Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor-I. Proc Natl Acad Sci USA 87:3690-3694.
30. Bitterman PB, Adelberg S, and Crystal RG (1983) Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders. J Clin Invest 72:1801-1813.
31. Blaschke S, Schulz H, Schwarz G, Blaschke V, Müller GA, and Reuss-Borst M (2001) Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol 28:12-21.
32. Blat C, Villaudy J, and Binoux M (1994) In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93:2286-2290.
33. Bondy CA (1991) Transient IGF-I gene expression during the maturation of functionally related central projection neurons. J Neurosci 11:3442-3455.
34. Bonner-Weir S and Smith FE (1994) Islet cell growth and the growth factors involved. Trends Endocrinol Metab 5:60-64.
35. Braulke T (1999) Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 31:242-246.
36. Brevetti G, Colao A, Schiano V, Pivonello R, Laurenzano E, Di Somma C, Lombardi G, and Chiariello M (2008) IGF system and peripheral arterial disease: relationship with disease severity and inflammatory status of the affected limb. Clin Endocrinol (Oxf) 69:894-900.
37. Brissenden JE, Ullrich A, and Francke U (1984) Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 310:781-784.
38. Brix TH, Christensen K, Holm NV, Harvald B, and Hegedüs L (1998) A population-based study of Graves' disease in Danish twins. Clin Endocrinol (Oxf) 48:397-400.
39. Brown TJ, Ercolani L, and Ginsberg BH (1983) Properties and regulation of the T lymphocyte insulin receptor. J Recept Res 3:481-494.
40. Bryant-Greenwood GD and Schwabe C (1994) Human relaxins: chemistry and biology. Endocr Rev 15:5-26.
41. Brzozowski AM, Dodson EJ, Dodson GG, Murshudov GN, Verma C, Turkenburg JP, de Bree FM, and Dauter Z (2002) Structural origins of the functional divergence of human insulin-like growth factor-I and insulin. Biochemistry 41:9389-9397.
42. Buckley DA, Loughran G, Murphy G, Fennelly C, and O'Connor R (2002) Identification of an IGF-1R kinase regulatory phosphatase using the fission yeast Schizosaccharomyces pombe and a GFP tagged IGF-1R in mammalian cells. Mol Pathol 55:46-54.
43. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, et al. (2003) A fully human monoclonal antibody to the insulin-like growth factor-I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912-8921.
44. Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL, LeRoith D, and Pouliki V (1998) Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res 58:3021-3027.
45. Buttgereit F, Burmester GR, and Brand MD (2000) Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 21:192-199.
46. Calderari S, Gangnerau MN, Thibault M, Meile MJ, Kassis N, Alvarez C, Portha B, and Serradas P (2007) Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto-Kakizaki rat model of type 2 diabetes. Diabetologia 50:1463-1471.
47. Carpenter G (1999) Employment of the epidermal growth factor receptor in growth Factor-Independent signaling pathways. J Cell Biol 146:697-702. (Pubitemid 29408896)
48. Casellas A, Salavert A, Agudo J, Ayuso E, Jimenez V, Moya M, Muñoz S, Franckhauser S, and Bosch F (2006) Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes. Diabetes 55:3246-3255. (Pubitemid 44923580)
49. Cass LA and Meinkoth JL (1998) Differential effects of cyclic adenosine 3′,5′-monophosphate on p70 ribosomal S6 kinase. Endocrinology 139:1991-1998. (Pubitemid 28513861)
50. Center DM, Kornfeld H, and Cruikshank WW (1997) Interleukin-16. Int J Biochem Cell Biol 29:1231-1234.
51. Chandrasekaran S, Guo NH, Rodrigues RG, Kaiser J, and Roberts DD (1999) Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by α3β1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem 274:11408-11416. (Pubitemid 129528358)
52. Chatenoud L, Thervet E, Primo J, and Bach JF (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91:123-127. (Pubitemid 24018655)
53. Chen W, Salojin KV, Mi QS, Grattan M, Meagher TC, Zucker P, and Delovitch TL (2004) Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 145:627-638. (Pubitemid 38183805)
54. Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:458-466. (Pubitemid 351733422)
55. Choyke PL, Zeman RK, Gootenberg JE, Greenberg JN, Hoffer F, and Frank JA (1987) Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. AJR Am J Roentgenol 149:269-272. (Pubitemid 17104977)
56. Christodoulakos GE, Lambrinoudaki IV, Economou EV, Papadias C, Vitoratos N, Panoulis CP, Kouskouni EE, Vlachou SA, and Creatsas GC (2007) Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. Atherosclerosis 193:142-150. (Pubitemid 46776695)
57. Clark R (1997) The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 18:157-179.
58. Clark R, Strasser J, McCabe S, Robbins K, and Jardieu P (1993) Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 92:540-548. (Pubitemid 23262369)
59. Clément S, Refetoff S, Robaye B, Dumont JE, and Schurmans S (2001) Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology 142:5131-5139. (Pubitemid 33131939)
60. Clemmons DR (2001) IGF-1 receptor-mediated signal transduction, in Targets for Growth Hormone and IGF-1 Action (Bouillon R ed), pp 17-28, Bioscientifica Ltd, Bristol, UK.
61. Clemmons DR (2007) Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6:821-833.
62. Clemmons DR and Maile LA (2005) Interaction between insulin-like growth factor-I receptor and αVβ3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs. Mol Endocrinol 19:1-11.
63. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, and Ruckle J (2000) The combination of insulin-like growth factor-I and insulin-like growth factorbinding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85:1518-1524. (Pubitemid 32289494)
64. Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, and Allan G (2005) Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274. (Pubitemid 41093731)
65. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073. (Pubitemid 40471873)
66. Colangelo LA, Chiu B, Kopp P, Liu K, and Gapstur SM (2009) Serum IGF-I and C-reactive protein in healthy black and white young men: the CARDIA male hormone study. Growth Horm IGF Res 19:420-425.
67. Cortez AB, Van Dop C, Bailey RC, Bersch N, Scott M, Golde DW, and Geffner ME (1996) IGF-I resistance in virus-transformed B-lymphocytes from African Efe Pygmies. Biochem Mol Med 58:31-36. (Pubitemid 26230526)
68. Craparo A, O'Neill TJ, and Gustafson TA (1995) Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor-I receptor. J Biol Chem 270:15639-15643.
69. Cwyfan Hughes SC, Cotterill AM, Molloy AR, Cassell TB, Braude N, Hinds CJ, Wass JA, and Holly JM (1992) The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery. J Endocrinol 135:135-145.
70. Davies TF (1996) Graves' disease, in Werner and Ingbar's The Thyroid (Braverman LE and Utiger RD eds) pp 525-558, Lippincott-Raven, Philadelphia.
71. Delbé J, Blat C, Desauty G, and Harel L (1991) Presence of IDF45 (mlGFBP-3) binding sites on chick embryo fibroblasts. Biochem Biophys Res Commun 179:495-501.
72. de Mello-Coelho V, Villa-Verde DM, Dardenne M, and Savino W (1997) Pituitary hormones modulate cell-cell interactions between thymocytes and thymic pithelial cells. J Neuroimmunol 76:39-49. (Pubitemid 27272627)
73. de Mello Coelho V, Villa-Verde DM, Farias-de-Oliveira DA, de Brito JM, Dardenne M, and Savino W (2002) Functional insulin-like growth factor-1/insulin-like growth factor-1 receptor-mediated circuit in human and murine thymic epithelial cells. Neuroendocrinology 75:139-150. (Pubitemid 34195774)
74. De Meyts P and Whittaker J (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1:769-783. (Pubitemid 37361561)
75. Denko CW and Malemud CJ (2004) Age-related changes in serum growth hormone, insulin-like growth factor-1 and somatostatin in system lupus erythematosus. BMC Musculoskelet Disord 5:37.
76. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, and Amiot M (2009) A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 100:366-369.
77. pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 177:4218-4223.
78. Dey BR, Frick K, Lopaczynski W, Nissley SP, and Furlanetto RW (1996) Evidence for the direct interaction of the insulin-like growth factor-I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol 10:631-641. (Pubitemid 26176271)
79. DiFedele LM, He J, Bonkowski EL, Han X, Held MA, Bohan A, Menon RK, and Denson LA (2005) Tumor necrosis factor α blockade restores growth hormone signaling in murine colitis. Gastroenterology 128:1278-1291. (Pubitemid 40712179)
80. Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, Huang F, Hession C, Flavier A, Favis M, Tran H, et al. (2009) Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem 284:10254-10267.
81. Dorman JB, Albinder B, Shroyer T, and Kenyon C (1995) The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 141:1399-1406.
82. Dörner T, Radbruch A, and Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433-441.
83. Douglas RS, Gianoukakis AG, Kamat S, and Smith TJ (2007) Aberrant expression of the IGF-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 178:3281-3287. (Pubitemid 46333212)
84. Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, Kamat S, and Smith TJ (2008) B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 181:5768-5774.
85. Douglas RS, Brix TH, Hwang CJ, Hegedüs L, and Smith TJ (2009) Divergent frequencies of IGF-1 receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors. J Clin Endocrinol Metab 94:1797-1802.
86. Drop SL, Schuller AG, Lindenbergh-Kortleve DJ, Groffen C, Brinkman A, and Zwarthoff EC (1992) Structural aspects of the IGFBP family. Growth Regul 2:69-79.
87. Du J, Peng T, Scheidegger KJ, and Delafontaine P (1999) Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 19:2119-2126. (Pubitemid 29422243)
88. Du J, Brink M, Peng T, Mottironi B, and Delafontaine P (2001) Thrombin regulates insulin-like growth factor-1 receptor transcription in vascular smooth muscle: characterization of the signaling pathway. Circ Res 88:1044-1052. (Pubitemid 34137117)
89. Duquesnoy RJ and Pedersen GM (1981) Immunologic and hematologic deficiencies of the hypopituitary dwarf mouse, in Immunologic Defects in Laboratory Animals (Gershwin ME and Merchant B eds) vol 1, pp 309-324, Plenum Publishing, New York.
90. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, and Weinberg RA (1993) Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45-51. (Pubitemid 23144959)
91. Eisenbarth GS, Ziegler AG, and Colman PA (1994) Pathogenesis of insulin-dependent (type I) diabetes mellitus, in Joslin's Diabetes Mellitus (Kahn CR and Weir GC eds) ed 13, pp 216-239, Lea and Febiger, Philadelphia.
92. Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, and Dahlerup JF (2007) The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. Scand J Gastroenterol 42:464-470. (Pubitemid 46569399)
93. Eizirik DL, Colli ML, and Ortis F (2009) The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 5:219-226.
94. El-Shewy HM, Kelly FL, Barki-Harrington L, and Luttrell LM (2004) Ectodomain shedding-dependent transactivation of epidermal growth factor receptors in response to insulin-like growth factor type I. Mol Endocrinol 18:2727-2739. (Pubitemid 39482061)
95. El-Shewy HM, Lee MH, Obeid LM, Jaffa AA, and Luttrell LM (2007) The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J Biol Chem 282:26150-26157.
96. El Yafi F, Winkler R, Delvenne P, Boussif N, Belaiche J, and Louis E (2005) Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clin Exp Immunol 139:526-533. (Pubitemid 40333265)
97. Fabris N, Pierpaoli W, and Sorkin E (1971) Hormones and the immunological capacity. 3. The immunodeficiency disease of the hypopituitary Snell-Bagg dwarf mouse. Clin Exp Immunol 9:209-225.
98. Fairweather D, Frisancho-Kiss S, and Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600-609.
99. Falanga V, Tiegs SL, Alstadt SP, Roberts AB, and Sporn MB (1987) Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 89:100-104. (Pubitemid 17084193)
100. Fawzi MM, Tawfik SO, Eissa AM, El-Komy MH, Abdel-Halim MR, and Shaker OG (2008) Expression of insulin-like growth factor-I in lesional and non-lesional skin of patients with morphoea. Br J Dermatol 159:86-90.
101. Feliciello A, Porcellini A, Ciullo I, Bonavolontà G, Avvedimento EV, and Fenzi G (1993) Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 342:337-338. (Pubitemid 23227563)
102. Feng Y and Dimitrov DS (2008) Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 11:178-185. (Pubitemid 351281057)
103. Fernihough JK, Billingham ME, Cwyfan-Hughes S, and Holly JM (1996) Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum 39:1556-1565. (Pubitemid 26314990)
104. Firth SM and Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854. (Pubitemid 35454590)
105. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, et al. (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 40:710-712. (Pubitemid 351748865)
106. Fournier T, Riches DW, Winston BW, Rose DM, Young SK, Noble PW, Lake FR, and Henson PM (1995) Divergence in macrophage insulin-like growth factor-I (IGF-I) synthesis induced by TNF-α and prostaglandin E2. J Immunol 155:2123-2133.
107. Fowlkes JL and Serra DM (1996) Characterization of glycosaminoglycan- binding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 271:14676-14679. (Pubitemid 26194941)
108. Fowlkes JL, Thrailkill KM, George-Nascimento C, Rosenberg CK, and Serra DM (1997) Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology 138:2280-2285. (Pubitemid 27215226)
109. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, et al. (2008) Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 40:713-715. (Pubitemid 351748866)
110. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, and Vigneri R (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23-37. (Pubitemid 351998752)
111. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, and Thompson CB (2002) The CD28 signaling pathway regulates glucose metabolism. Immunity 16:769-777.
112. Frauwirth KA and Thompson CB (2004) Regulation of T lymphocyte metabolism. J Immunol 172:4661-4665.
113. Freund GG, Kulas DT, and Mooney RA (1993) Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 151:1811-1820.
114. Freund GG, Kulas DT, Way BA, and Mooney RA (1994) Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54:3179-3185. (Pubitemid 24980048)
115. Geffner ME, Kaplan SA, Bersch N, Lippe BM, Smith WG, Nagel RA, Santulli TV Jr, Li CH, and Golde DW (1987) Leprechaunism: in vitro insulin action despite genetic insulin resistance. Pediatr Res 22:286-291. (Pubitemid 17162790)
116. Geffner ME, Bersch N, and GoldeDW(1992) Insulin and IGF-I stimulate normal and virally transformed T-lymphocyte cell growth in vitro. Brain Behav Immun 6:377-386.
117. Geffner ME, Bailey RC, Bersch N, Vera JC, and Golde DW (1993) Insulin-like growth factor-I unresponsiveness in an Efe Pygmy. Biochem Biophys Res Commun 193:1216-1223. (Pubitemid 23209724)
118. Geffner ME, Bersch N, Bailey RC, and Golde DW (1995) Insulin-like growth factor-I resistance in immortalized T cell lines from African Efe Pygmies. J Clin Endocrinol Metab 80:3732-3738.
119. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, and Bosch F (2002) β Cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 109:1153-1163. (Pubitemid 34496593)
120. Ghosh P, Dahms NM, and Kornfeld S (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4:202-212. (Pubitemid 36288042)
121. Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, and Smith TJ (2006) IgG from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology 147:1941-1949.
122. Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, and Robbins P (2000) Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor-I. Gene Ther 7:2015-2022. (Pubitemid 32036767)
123. Gibson LF, Piktel D, and Landreth KS (1993) Insulin-like growth factor-1 potentiates expansion of interleukin-7-dependent pro-B cells. Blood 82:3005-3011. (Pubitemid 23334926)
124. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, and Axelson M (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64:236-242. (Pubitemid 38114104)
125. Giuliani C, Saji M, Bucci I, Fiore G, Liberatore M, Singer DS, Monaco F, Kohn LD, and Napolitano G (2006) Transcriptional regulation of major histocompatibility complex class I gene by insulin and IGF-I in FRTL-5 thyroid cells. J Endocrinol 189:605-615. (Pubitemid 43919235)
126. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, and Corvaia N (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and antiepidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316-328. (Pubitemid 39628325)
127. Grønborg M, Wulff BS, Rasmussen JS, Kjeldsen T, and Gammeltoft S (1993) Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase. J Biol Chem 268:23435-23440. (Pubitemid 23328068)
128. Grounds MD (2002) Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology 3:19-24.
129. Grounds MD, Radley HG, Gebski BL, Bogoyevitch MA, and Shavlakadze T., Radley HG, Gebski BL, Bogoyevitch MA, and Shavlakadze T (2008) Implications of crosstalk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Clin Exp Pharmacol Physiol 35:846-851. (Pubitemid 351725233)
130. Guzman Moreno R (2009) B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev 8:585-590.
131. Hackel PO, Zwick E, Prenzel N, and Ullrich A (1999) Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-189. (Pubitemid 29164032)
132. Hadden JW, Malec PH, Coto J, and Hadden EM (1992) Thymic involution in aging. Prospects for correction. Ann NY Acad Sci 673:231-239.
133. Han X, Sosnowska D, Bonkowski EL, and Denson LA (2005) Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology 129:185-203. (Pubitemid 41002054)
134. th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, CA. Poster B210.
135. Harrison NK, Cambrey AD, Myers AR, Southcott AM, Black CM, du Bois RM, Laurent GJ, and McAnulty RJ (1994) Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Lond) 86:141-148.
136. Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM, Du Bois RM, and Turner-Warwick M (1991) Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144:706-713.
137. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, et al. (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954-966. (Pubitemid 44411958)
138. Hassan AB (2003) Keys to the hidden treasures of the mannose 6-phosphate/insulin-like growth factor 2 receptor. Am J Pathol 162:3-6.
139. Hattori Y, Vera JC, Rivas CI, Bersch N, Bailey RC, Geffner ME, and Golde DW (1996) Decreased insulin-like growth factor-I receptor expression and function in immortalized African Pygmy T cells. J Clin Endocrinol Metab 81:2257-2263. (Pubitemid 26175954)
140. Helderman JH and Strom TB (1977) Emergence of insulin receptors upon alloimmune T cells in the rat. J Clin Invest 59:338-344.
141. Helderman JH and Strom TB (1978) Specific insulin binding site on T and B lymphocytes as a marker of cell activation. Nature 274:62-63.
142. Helderman JH (1981) Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. J Clin Invest 67:1636-1642.
143. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698. (Pubitemid 34547482)
144. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, and Bahn RS (1993) Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 3:297-300. (Pubitemid 24015323)
145. Heulin MH, Artur M, Straczek J, Belleville F, Nabet P, Hermann A, Lebeurre MD, and Schimpff RM (1982) Effect of low molecular weight human serum factors and human somatomedin peptides on human lymphocyte cultures. J Cell Sci 57:129-137. (Pubitemid 13220113)
146. Higano C, LoRusso P, Gordon M, Yu EY, Whiting SH, Fox F, Katz T, Rowinsky E, Youssoufian H (2007) A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis, in 19th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, CA. Poster B19.
147. Hijikawa T, Kaibori M, Uchida Y, Yamada M, Matsui K, Ozaki T, Kamiyama Y, Nishizawa M, and Okumura T (2008) Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-α and iNOS induction in D-galactosamine and LPS-treated rats. Shock 29:740-747. (Pubitemid 351769938)
148. Himpe E, Degaillier C, Coppens A, and Kooijman R (2008) Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. J Endocrinol 199:69-80.
149. Hinton PS, Peterson CA, Dahly EM, and Ney DM (1998) IGF-I alters lymphocyte survival and regeneration in thymus and spleen after dexamethasone treatment. Am J Physiol 274:R912-R920. (Pubitemid 28217740)
150. Holzenberger M, Dupont J, Ducos B, Leneuve P, Géloën A, Even PC, Cervera P, and Le Bouc Y (2003) IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421:182-187. (Pubitemid 36090987)
151. Hunt P and Eardley DD (1986) Suppressive effects of insulin and insulin-like growth factor-1 (IGF1) on immune responses. J Immunol 136:3994-3999. (Pubitemid 16123041)
152. Hwa V, Oh Y, and Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787. (Pubitemid 30648894)
153. Imai K and Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714-727. (Pubitemid 44286003)
154. Jain S, Golde DW, Bailey R, and Geffner ME (1998) Insulin-like growth factor-I resistance. Endocr Rev 19:625-646.
155. Jansson M, Uhlen M, and Nilsson B (1997) Structural changes in insulin-like growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor. Biochemistry 36:4108-4117. (Pubitemid 27171582)
156. Jardieu P, Clark R, Mortensen D, and Dorshkind K (1994) In vivo administration of insulin-like growth factor-I stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation. J Immunol 152:4320-4327.
157. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, and Thomas G (1997) Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16:3693-3704. (Pubitemid 27250062)
158. Jelinek DF, Witzig TE, and Arendt BK (1997) A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159:487-496. (Pubitemid 127493736)
159. Jeschke MG, Barrow RE, and Herndon DN (2000) Insulinlike growth factor-I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 231:246-252.
160. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, et al. (2007) A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 6:2158-2167. (Pubitemid 47294744)
161. Johnson EW, Jones LA, and Kozak RW (1992) Expression and function of insulin-like growth factor receptors on anti-CD3-activated human T lymphocytes. J Immunol 148:63-71.
162. Jones JI and Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34.
163. Jones JI, Gockerman A, Busby WH Jr., Wright G, and Clemmons DR (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the α5β1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90:10553-10557. (Pubitemid 23347080)
164. Jones JI, Prevette T, Gockerman A, and Clemmons DR (1996) Ligand occupancy of the α-V-β3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 93:2482-2487. (Pubitemid 26104797)
165. Kaleko M, Rutter WJ, and Miller AD (1990) Overexpression of the human insulin-like growth factor-I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10:464-473. (Pubitemid 20034451)
166. Kammer GM, Perl A, Richardson BC, and Tsokos GC (2002) Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 46:1139-1154. (Pubitemid 34525819)
167. Kant SG, Kriek M, Walenkamp MJ, Hansson KB, van Rhijn A, Clayton-Smith J, Wit JM, and Breuning MH (2007) Tall stature and duplication of the insulin-like growth factor-I receptor gene. Eur J Med Genet 50:1-10. (Pubitemid 46097574)
168. Kato H, Faria TN, Stannard B, Roberts CT Jr., and LeRoith D (1993) Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (αIR-3). J Biol Chem 268:2655-2661. (Pubitemid 23057892)
169. Kato H, Faria TN, Stannard B, Roberts CT Jr., and LeRoith D (1994) Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol 8:40-50. (Pubitemid 24985667)
170. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, and Tsianos EV (2001) Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 11:364-367. (Pubitemid 34428879)
171. Kavurma MM, Figg N, Bennett MR, Mercer J, Khachigian LM, and Littlewood TD (2007) Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. Biochem J 407:79-87. (Pubitemid 47535583)
172. Kecha O, Brilot F, Martens H, Franchimont N, Renard C, Greimers R, Defresne MP, Winkler R, and Geenen V (2000) Involvement of insulin-like growth factors in early T cell development: a study using fetal thymic organ cultures. Endocrinology 141:1209-1217. (Pubitemid 32260464)
173. Kelly-Welch AE, Wang HY, Wang LM, Pierce JH, Jay G, Finkelman F, and Keegan AD (2004) Transgenic expression of insulin receptor substrate 2 in murine B cells alters the cell density-dependence of IgE production in vitro and enhances IgE production in vivo. J Immunol 172:2803-2810. (Pubitemid 38263664)
174. Kelley KW, Arkins S, Minshall C, Liu Q, and Dantzer R (1996) Growth hormone, growth factors and hematopoiesis. Horm Res 45:38-45.
175. Kennington WJ, Hoffmann AA, and Partridge L (2007) Mapping regions within cosmopolitan inversion In(3R)Payne associated with natural variation in body size in Drosophila melanogaster. Genetics 177:549-556.
176. Kennington WJ, Partridge L, and Hoffmann AA (2006) Patterns of diversity and linkage disequilibrium within the cosmopolitan inversion In(3R)Payne in Drosophila melanogaster are indicative of coadaptation. Genetics 172:1655-1663.
177. Kenyon C, Chang J, Gensch E, Rudner A, and Tabtiang R (1993) A C. elegans mutant that lives twice as long as wild type. Nature 366:461-464. (Pubitemid 24013878)
178. Keyszer GM, Heer AH, Kriegsmann J, Geiler T, Keysser C, Gay RE, and Gay S (1995) Detection of insulin-like growth factor-I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol 22:275-281.
179. Khan IU, Tsokos GC, and Kammer GM (2003) Abnormal B cell signal transduction in systemic lupus erythematosus. Curr Dir Autoimmun 6:89-104.
180. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, and Accili D (2002) Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 277:36740-36747.
181. Kim SY, Toretsky JA, Scher D, and Helman LJ (2009) The role of IGF-1R in pediatric malignancies. The Oncologist 14:83-91.
182. Kimata H and Fujimoto M (1994) Growth hormone and insulin-like growth factor-I induce immunoglobulin (Ig)E and IgG4 production by human B cells. J Exp Med 180:727-732. (Pubitemid 24224153)
183. Kimata H and Yoshida A (1994a) Differential effect of growth hormone and insulin-like growth factor-I, insulin-like growth factor-II, and insulin on Ig production and growth in human plasma cells. Blood 83:1569-1574. (Pubitemid 24081571)
184. Kimata H and Yoshida A (1994b) Effect of growth hormone and insulin-like growth factor-I on immunoglobulin production by and growth of human B cells. J Clin Endocrinol Metab 78:635-641. (Pubitemid 24083304)
185. Kincade PW, Lee G, Pietrangeli CE, Hayashi S, and Gimble JM (1989) Cells and molecules that regulate B lymphopoiesis in bone marrow. Annu Rev Immunol 7:111-143. (Pubitemid 19138010)
186. Kirschner BS and Sutton MM (1986) Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 91:830-836. (Pubitemid 16014587)
187. Kirstein M, Aston C, Hintz R, and Vlassara H (1992) Receptor-specific induction of insulin-like growth factor-I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 90:439-446.
188. Klein JR (2003) Physiological relevance of thyroid stimulating hormone and thyroid stimulating hormone receptor in tissues other than the thyroid. Autoimmunity 36:417-421.
189. Kleinberg DL, Wood TL, Furth PA, and Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51-74.
190. Klimiuk PA, Goronzy JJ, and Weyand CM (1999) IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 162:4293-4299.
191. Kooijman R, Scholtens LE, Rijkers GT, and Zegers BJ (1995a) Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes. J Endocrinol 147:203-209.
192. Kooijman R, van Buul-Offers SC, Scholtens LE, Schuurman HJ, Van den Brande LJ, and Zegers BJ (1995b) T cell development in insulin-like growth factor-II transgenic mice. J Immunol 154:5736-5745.
193. Kooijman RK, Scholtens LE, Rijkers GT, and Zegers BJ (1995c) Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur J Immunol 25:931-935.
194. Kooijman R, Coppens A, and Hooghe-Peters E (2002) Igf-I inhibits spontaneous apoptosis in human granulocytes. Endocrinology 143:1206-1212. (Pubitemid 34274348)
195. Kooijman R and Coppens A (2004) Insulin-like growth factor-I stimulates IL-10 production in human T cells. J Leukoc Biol 76:862-867. (Pubitemid 39313723)
196. Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulin-like growth factor-II receptors. Annu Rev Biochem 61:307-330.
197. Krein PM and Winston BW (2002) Roles for insulin-like growth factor-I and transforming growth factor-beta in fibrotic lung disease. Chest 122 (6 Suppl):289S-293S.
198. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA, and Kahn CR (2002) β-Cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter β-cell mass. Nat Genet 31:111-115.
199. Kumagai J, Akiyama H, Iwashita S, Iida H, and Yahara I (1981) In vitro regeneration of resting lymphocytes from stimulated lymphocytes and its inhibition by insulin. J Immunol 126:1249-1254.
200. Kurtz A, Jelkmann W, and Bauer C (1982) A new candidate for the regulation of erythropoiesis. Insulin-like growth factor-I. FEBS Lett 149:105-108.
201. Krug U, Krug F, and Cuatrecasas P (1972) Emergence of insulin receptors on human lymphocytes during in vitro transformation. Proc Natl Acad Sci USA 69:2604-2608.
202. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564-569. (Pubitemid 47525141)
203. Landreth KS, Narayanan R, and Dorshkind K (1992) Insulin-like growth factor-I regulates pro-B cell differentiation. Blood 80:1207-1212.
204. Lawrence MC, McKern NM, and Ward CW (2007) Insulin receptor structure and its implications for the IGF-1 receptor. Current Opinion in Structural Biology 17:699-705. (Pubitemid 350180400)
205. Leal SM, Huang SS, and Huang JS (1999) Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem 274:6711-6717.
206. Lebrun P, Baron V, Hauck CR, Schlaepfer DD, and Van Obberghen E (2000) Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression. J Biol Chem 275:38371-38377. (Pubitemid 32009160)
207. Lebrun P, Mothe-Satney I, Delahaye L, Van Obberghen E, and Baron V (1998) Insulin receptor substrate-1 as a signaling molecule for focal adhesion kinase pp125(FAK) and pp60(src). J Biol Chem 273:32244-32253. (Pubitemid 29177171)
208. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, and Rosen CJ (2007) Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903-911.
209. Lee KW and Cohen P (2002) Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. J Endocrinol 175:33-40. (Pubitemid 35276584)
210. Lee PD, Rosenfeld RG, Hintz RL, and Smith SD (1986) Characterization of insulin, insulin-like growth factors I and II, and growth hormone receptors on human leukemic lymphoblasts. J Clin Endocrinol Metab 62:28-35. (Pubitemid 16186839)
211. Lee WH, Javedan S, and Bondy CA (1992) Coordinate expression of insulin-like growth factor system components by neurons and neuroglia during retinal and cerebellar development. J Neurosci 12:4737-4744.
212. Le Roith D, Kim H, Fernandez AM, and Accili D (2002) Inactivation of muscle insulin and IGF-I receptors and insulin responsiveness. Curr Opin Clin Nutr Metab Care 5:371-375. (Pubitemid 40684657)
213. LeRoith D, Werner H, Beitner-Johnson D, and Roberts CT Jr (1995) Molecular and cellular aspects of the insulin-like growth factor-I receptor. Endocr Rev 16:143-163. (Pubitemid 26169120)
214. LeRoy EC, Mercurio S, and Sherer GK (1982) Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors. Proc Natl Acad Sci USA 79:1286-1290. (Pubitemid 12105593)
215. Li SL, Kato J, Paz IB, Kasuya J, and Fujita-Yamaguchi Y (1993) Two new monoclonal antibodies against the α subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun 196:92-98. (Pubitemid 23309479)
216. Ling Y, Maile LA, and Clemmons DR (2003) Tyrosine phosphorylation of the β3-subunit of the αVβ3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor-I receptor. Mol Endocrinol 17:1824-1833. (Pubitemid 37072298)
217. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, and Cohen P (2000) Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-α regulate transcriptional signaling and apoptosis. J Biol Chem 275:33607-33613.
218. Liu JP, Baker J, Perkins AS, Robertson EJ, and Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor-I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72. (Pubitemid 23306021)
219. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, and Yung WK (2007) Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6:1357-1367. (Pubitemid 46711999)
220. Liu X, Yao DL, Bondy CA, Brenner M, Hudson LD, Zhou J, and Webster HD (1994) Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci 5:418-430. (Pubitemid 24314413)
221. Lobie PE, Breipohl W, and Waters MJ (1990) Growth hormone receptor expression in the rat gastrointestinal tract. Endocrinology 126:299-306. (Pubitemid 20037157)
222. Long E, Huynh HT, and Zhao X (1998) Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors. Endocrine 9:185-192. (Pubitemid 28520973)
223. Luttrell LM, Daaka Y, and Lefkowitz RJ (1999) Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 11:177-183. (Pubitemid 29164031)
224. Maake C, Yamamoto H, and Murphy LJ (1997) The growth hormone dependent serine protease inhibitor, Spi 2.1 inhibits the des (1-3) insulin-like growth factor-I generating protease. Endocrinology 138:5630-5636.
225. Maile LA and Clemmons DR (2002a) Regulation of insulin-like growth factor-I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. J Biol Chem 277:8955-8960.
226. Maile LA and Clemmons DR (2002b) Regulation of insulin-like growth factor-I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. J Biol Chem 277:8955-8960.
227. Maile LA and Clemmons DR (2002c) The αVβ3 integrin regulates insulin-like growth factor-I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor. Endocrinology 143:4259-4264.
228. Maile LA and Clemmons DR (2003) Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Circ Res 93:925-931. (Pubitemid 37433230)
229. Maiter D, Underwood LE, Maes M, and Ketelslegers JM (1988) Acute down-regulation of the somatogenic receptors in rat liver by a single injection of growth hormone. Endocrinology 122:1291-1296. (Pubitemid 18091955)
230. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, and Singh R (2003) An anti-insulin-like growth factor-I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083. (Pubitemid 37022647)
231. Mañes S, Llorente M, Lacalle RA, Gómez-Moutón C, Kremer L, Mira E, and Martínez-A C (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935-6945. (Pubitemid 129504976)
232. Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández- Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, and Martínez-A C (1997) Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272:25706-25712.
233. Martin JL and Baxter RC (2007) Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 148:2532-2541.
234. Matsumoto T, Gargosky SE, Iwasaki K, and Rosenfeld RG (1996) Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 81:150-155. (Pubitemid 26035017)
235. Matsumoto T and Tsurumoto T (2002) Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford) 41:352-353. (Pubitemid 34537879)
236. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, Francis IR, Gross BH, and Grant RM (1998) High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 101:2301-2308. (Pubitemid 28270424)
237. McElroy B, Powell JC, and McCarthy JV (2007) The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. Biochem Biophys Res Commun 358:1136-1141. (Pubitemid 46829007)
238. McMorris FA, Smith TM, DeSalvo S, and Furlanetto RW (1986) Insulin-like growth factor-I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 83:822-826. (Pubitemid 16035567)
239. Medsger TA Jr (1985) Systemic sclerosis, eosinophilic fasciitis and calcinosis, in Arthritis and Allied Conditions (McCarty DJ ed) pp 966-1036, Lea and Febiger, Philadelphia.
240. Megyesi K, Kahn CR, Roth J, Neville DM Jr., Nissley SP, Humbel RE, and Froesch ER (1975) The NSILA-s receptor in liver plasma membranes. Characterization and comparison with the insulin receptor. J Biol Chem 250:8990-8996.
241. Mellman I (1996) Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12:575-625.
242. Merchav S, Tatarsky I, and Hochberg Z (1988) Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor-I/somatomedin C and human growth hormone. J Clin Invest 81:791-797. (Pubitemid 18079727)
243. Miller RA (1996) The aging immune system: primer and prospectus. Science 273:70-74.
244. Mintz L, Galperin E, Pasmanik-Chor M, Tulzinsky S, Bromberg Y, Kozak CA, Joyner A, Fein A, and Horowitz M (1999) EHD1 - an EH-domain-containing protein with a specific expression pattern. Genomics 59:66-76. (Pubitemid 29339874)
245. Misbin RI and Almira EC (1989) Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14- and B26-[125I] monoiodoinsulin. Diabetes 38:152-158.
246. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230. (Pubitemid 38402114)
247. Moldawer LL and Copeland EM 3rd (1997) Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 79:1828-1839.
248. Mondschein JS, Smith SA, Hammond JM, Smith SA and Hammond JM (1990) Production of insulin-like growth factor binding proteins (IGFBPs) by porcine granulosa cells: identification of IGFBP-2 and -3 and regulation by hormones and growth factors. Endocrinology 127:2298-2306.
249. Montecino-Rodriguez E and Dorshkind K (1997) Thymocyte development in vitro: implications for studies of ageing and thymic involution. Mech Ageing Dev 93:47-57. (Pubitemid 27138328)
250. Montecino-Rodriguez E, Clark R, and Dorshkind K (1998) Effects of insulin-like growth factor administration and bone marrow transplantation on thymopoiesis in aged mice. Endocrinology 139:4120-4126. (Pubitemid 28513697)
251. Moralez AM, Maile LA, Clarke J, Busby WH Jr, and Clemmons DR (2005) Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-1 actions. J Cell Physiol 203:328-334. (Pubitemid 40471766)
252. Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, and Defilippi P (1998) Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J 17:6622-6632. (Pubitemid 28521796)
253. Mulvihill MJ, Ji QS, Werner D, Beck P, Cesario C, Cooke A, Cox M, Crew A, Dong H, Feng L, et al. (2007) 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem Lett 17:1091-1097.
254. Murphy LJ (2006) Insulin-like growth factor-I: a treatment for type 2 diabetes revisited. Endocrinology 147:2616-2618.
255. Murphy WJ, Durum SK, and Longo DL (1992a) Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. Proc Natl Acad Sci USA 89:4481-4485.
256. Murphy WJ, Durum SK, and Longo DL (1992b) Role of neuroendocrine hormones in murine T cell development. Growth hormone exerts thymopoietic effects in vivo. J Immunol 149:3851-3857.
257. Murphy WJ, Durum SK, and Longo DL (1993) Differential effects of growth hormone and prolactin on murine T cell development and function. J Exp Med 178:231-236.
258. Murphy WJ, Tsarfaty G, and Longo DL (1992c) Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 80:1443-1447.
259. Myers SE, Cheung PT, Handwerger S, and Chernausek SD (1993) Insulin-like growth factor-I (IGF-I) enhanced proteolysis of IGF-binding protein-4 in conditioned medium from primary cultures of human decidua: independence from IGF receptor binding. Endocrinology 133:1525-1531. (Pubitemid 23295175)
260. Nagaoka I, Trapnell BC, and Crystal RG (1990) Regulation of insulin-like growth factor-I gene expression in the human macrophage-like cell line U937. J Clin Invest 85:448-455. (Pubitemid 20070051)
261. Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, and McCune JM (2002) Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16:1103-1111. (Pubitemid 34533848)
262. Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, Clor JL, Epling L, Sinclair E, Baum PD, et al. (2008) Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 118:1085-1098. (Pubitemid 351364616)
263. Neely EK, Smith SD, and Rosenfeld RG (1991) Human leukemic T and B lymphoblasts produce insulin-like growth factor binding proteins 2 and 4. Acta Endocrinol (Copenh) 124:707-714.
264. Neidel J, Blum WF, Schaeffer HJ, Schulze M, Schönau E, Lindschau J, and Föll J (1997) Elevated levels of insulin-like growth factor (IGF) binding protein-3 in rheumatoid arthritis synovial fluid inhibit stimulation by IGF-I of articular chondrocyte proteoglycan synthesis. Rheumatol Int 17:29-37. (Pubitemid 27239285)
265. Nguyen BY, Clerici M, Venzon DJ, Bauza S, Murphy WJ, Longo DL, Baseler M, Gesundheit N, Broder S, Shearer G, et al. (1998) Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 12:895-904. (Pubitemid 28241403)
266. Noble PW, Lake FR, Henson PM, and Riches DW (1993) Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-α-dependent mechanism in murine macrophages. J Clin Invest 91:2368-2377.
267. O'Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, and Kelley KW (2008) Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol 252:91-110.
268. Oh Y, Müller HL, Lamson G, and Rosenfeld RG (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971. (Pubitemid 23206645)
269. Oliver SE, Barrass B, Gunnell DJ, Donovan JL, Peters TJ, Persad RA, Gillatt D, Neal DE, Hamdy FC, and Holly JM (2004) Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 13:163-165. (Pubitemid 38116636)
270. th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, CA. Poster A63.
271. Oster MH, Fielder PJ, Levin N, and Cronin MJ (1995) Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. J Clin Invest 95:2258-2265.
272. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, and Belfiore A (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5:1935-1944. (Pubitemid 29334478)
273. Park ES, Kim H, Suh JM, Park SJ, Kwon OY, Kim YK, Ro HK, Cho BY, Chung J, and Shong M (2000a) Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells. Mol Endocrinol 14:440-448. (Pubitemid 32260535)
274. Park ES, Kim H, Suh JM, Park SJ, You SH, Chung HK, Lee KW, Kwon OY, Cho BY, Kim YK, et al. (2000b) Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway. Mol Endocrinol 14:662-670. (Pubitemid 32260510)
275. Park YJ, Kim TY, Lee SH, Kim H, Kim SW, Shong M, Yoon YK, Cho BY, and Park DJ (2005) p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling. Endocrinology 146:2473-2480. (Pubitemid 40577536)
276. Parker A, Rees C, Clarke J, Busby WH Jr., and Clemmons DR (1998) Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. Mol Biol Cell 9:2383-2392. (Pubitemid 28425883)
277. Parker A, Clarke JB, Busby WH Jr., and Clemmons DR (1996) Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5. J Biol Chem 271:13523-13529. (Pubitemid 26185396)
278. Parmentier M, Libert F, Maenhaut C, Lefort A, Gérard C, Perret J, Van Sande J, Dumont JE, and Vassart G (1989) Molecular cloning of the thyrotropin receptor. Science 246:1620-1622.
279. Parry RV, Reif K, Smith G, Sansom DM, Hemmings BA, and Ward SG (1997) Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur J Immunol 27:2495-2501. (Pubitemid 27453836)
280. Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, and LeRoith D (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619-2630. (Pubitemid 43764594)
281. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
282. Pollak MN, Lacy MQ, Lipton A, Demers L, Leitzel K, de Bono JS, Yin D, Roberts L, Sharma A, and Gualberto A(2007) Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. J Clin Oncol 25 (Suppl 18S):3587.
283. Pollak MN, Schernhammer ES, and Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518.
284. Poulin JF, Viswanathan MN, Harris JM, Komanduri KV, Wieder E, Ringuette N, Jenkins M, McCune JM, and Sékaly RP (1999) Direct evidence for thymic function in adult humans. J Exp Med 190:479-486. (Pubitemid 29395376)
285. Prabhakar BS, Bahn RS, and Smith TJ (2003) Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835. (Pubitemid 38067700)
286. Pritchard J, Horst N, Cruikshank W, and Smith TJ (2002) Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942-950. (Pubitemid 34049599)
287. Pritchard J, Han R, Horst N, Cruikshank WW, and Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor-I receptor pathway. J Immunol 170:6348-6354. (Pubitemid 36682621)
288. Pritchard J, Tsui S, Horst N, Cruikshank WW, and Smith TJ (2004) Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol 173:3564-3569. (Pubitemid 39142068)
289. Prummel MF, Strieder T, and Wiersinga WM (2004) The environment and autoimmune thyroid diseases. Eur J Endocrinol 150:605-618.
290. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zimmermann EM, Sartor RB, and Lund PK (2000) IGF-I and procollagen α1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol 279:G1307-G1322.
291. Raine CS (1984) Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 50:608-635.
292. Rajaram S, Baylink DJ, and Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801-831. (Pubitemid 28009568)
293. Reiss K, Tu X, Romano G, Peruzzi F, Wang JY, and Baserga R (2001) Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors. Clin Cancer Res 7:2134-2144. (Pubitemid 32994854)
294. Resnicoff M and Baserga R (1998) The role of insulin-like growth factor-I receptor in transformation and apoptosis. Ann NY Acad Sci 842:76-81. (Pubitemid 28227009)
295. Ricort JM, Lombet A, Lassarre C, and Binoux M (2002) Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Lett 527:293-297. (Pubitemid 35253882)
296. Ricort JM and Binoux M (2002) Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J Biol Chem 277:19448-19454. (Pubitemid 34967454)
297. Ricort JM and Binoux M (2001) Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology 142:108-113. (Pubitemid 32183671)
298. Rinderknecht E and Humbel RE (1978) The amino acid sequence of human insulin-like growth factor-I and its structural homology with proinsulin. J Biol Chem 253:2769-2776. (Pubitemid 8326483)
299. Rivas-Santiago B, Hernandez-Pando R, Carranza C, Juarez E, Contreras JL, Aguilar-Leon D, Torres M, and Sada E (2008) Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 76:935-941. (Pubitemid 351428052)
300. Robbins K, McCabe S, Scheiner T, Strasser J, Clark R, and Jardieu P (1994) Immunological effects of insulin-like growth factor-I - enhancement of immunoglobulin synthesis. Clin Exp Immunol 95:337-342. (Pubitemid 24207150)
301. Rom WN, Basset P, Fells GA, Nukiwa T, Trapnell BC, and Crysal RG (1988) Alveolar macrophages release an insulin-like growth factor-I-type molecule. J Clin Invest 82:1685-1693. (Pubitemid 19007774)
302. Rom WN and Pääkkö P (1991) Activated alveolar macrophages express the insulin-like growth factor-I receptor. Am J Respir Cell Mol Biol 4:432-439.
303. th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, CA. Poster A77.
304. Rosen LB and Greenberg ME (1996) Stimulation of growth factor receptor signal transduction by activation of voltage-sensitive calcium channels. Proc Natl Acad Sci USA 93:1113-1118.
305. Rosenfeld RG, Hwa V, Wilson E, Plymate SR, and Oh Y (2000) The insulin-like growth factor-binding protein superfamily. Growth Horm IGF Res 10:S16-S17. (Pubitemid 30641918)
306. Rosette C and Karin M (1996) Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274:1194-1197. (Pubitemid 26389285)
307. Ross M, Francis GL, Szabo L, Wallace JC, and Ballard FJ (1989) Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J 258:267-272. (Pubitemid 19062278)
308. Rotem-Yehudar R, Galperin E, and Horowitz M (2001) Association of insulin-like growth factor 1 receptor with EHD1 and SNAP29. J Biol Chem 276:33054-33060. (Pubitemid 37384758)
309. Roth RA, Mesirow ML, Yokono K, and Baba S (1984) Degradation of insulin-like growth factors I and II by a human insulin degrading enzyme. Endocr Res 10:101-112. (Pubitemid 14037221)
310. Rothe MJ, Altman RD, and Falanga V (1988) Plasma somatomedin-C levels in systemic sclerosis. Br J Dermatol 119:639-642.
311. th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, CA. p C84.
312. Roudabush FL, Pierce KL, Maudsley S, Khan KD, and Luttrell LM (2000) Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 275:22583-22589. (Pubitemid 30621851)
313. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, and Ludwig DL (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor-I receptor. Clin Cancer Res 13:5549s-5555s. (Pubitemid 47510386)
314. Sachdev D, Singh R, Fujita-Yamaguchi Y, and Yee D (2006) Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66:2391-2402. (Pubitemid 43294955)
315. Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, and Elizalde PV (2004) Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23:5161-5174.
316. Salcini AE, Confalonieri S, Doria M, Santolini E, Tassi E, Minenkova O, Cesareni G, Pelicci PG, and Di Fiore PP (1997) Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev 11:2239-2249. (Pubitemid 27387974)
317. Salisbury AJ and Macaulay VM (2003) Development of molecular agents for IGF receptor targeting. Horm Metab Res 35:843-849.
318. Samani AA, Yakar S, LeRoith D, and Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47. (Pubitemid 46220849)
319. Savino W, Postel-Vinay MC, Smaniotto S, and Dardenne M (2002) The thymus gland: a target organ for growth hormone. Scand J Immunol 55:442-452. (Pubitemid 34451229)
320. Schalkwijk J, Joosten LA, van den Berg WB, van Wyk JJ, and van de Putte LB (1989) Insulin-like growth factor stimulation of chondrocyte proteoglycan synthesis by human synovial fluid. Arthritis Rheum 32:66-71. (Pubitemid 19034926)
321. Schall TJ, Bacon K, Toy KJ, and Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669-671.
322. Schillaci R, Brocardo MG, Galeano A, and Roldán A (1998) Downregulation of insulin-like growth factor-1 receptor (IGF-1R) expression in human T lymphocyte activation. Cell Immunol 183:157-161.
323. Schimpff RM, Repellin AM, Salvatoni A, Thieriot-Prevost G, and Chatelain P (1983) Effect of purified somatomedins on thymidine incorporation into lectin-activated human lymphocytes. Acta Endocrinol (Copenh) 102:21-26.
324. Schmid SL, McNiven MA, and De Camilli P (1998) Dynamin and its partners: a progress report. Curr Opin Cell Biol 10:504-512.
325. Schnitzer T, Keuenkele KP, Rebers F, Van Vugt M, Klein C, Lanzendoerfer M, Mundigl O, Parren PW, van de Winkel JG, and Schumacher R (2006) Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Eur J Cancer 42 (Suppl):66-67.
326. Schönland SO, Zimmer JK, Lopez-Benitez CM, Widmann T, Ramin KD, Goronzy JJ, and Weyand CM (2003) Homeostatic control of T-cell generation in neonates. Blood 102:1428-1434.
327. Sciaky D, Brazer W, Center DM, Cruikshank WW, and Smith TJ (2000) Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol 164:3806-3814.
328. Segretin ME, Galeano A, Roldán A, and Schillaci R (2003) Insulin-like growth factor-1 receptor regulation in activated human T lymphocytes. Horm Res 59:276-280.
329. Shakibaei M, John T, De Souza P, Rahmanzadeh R, and Merker HJ (1999) Signal transduction by β1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor. Biochem J 342:615-623.
330. Shawver LK, Slamon D, and Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117-123.
331. Siddle K, Soos MA, Field CE, and Navé BT (1994) Hybrid and atypical insulin/insulin-like growth factor-I receptors. Horm Res 41 (Suppl 2):56-65.
332. Simchen C, Lehmann I, Sittig D, Steinert M, and Aust G (2000) Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves' disease and thyroid autonomy and in thyroid-derived cell populations. J Clin Endocrinol Metab 85:4758-4764.
333. Skjaerbaek C, Frystyk J, Orskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, Møller N, and Flyvbjerg A (1998) Differential changes in free and total insulin-like growth factor-I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 83:2445-2449.
334. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, and McKinley MJ (2000) A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 342:1633-1637.
335. Smith TJ and Hoa N (2004) Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 89:5076-5080.
336. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, and Sorisky A (2002) Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385-392.
337. Smith TJ, Sempowski GD, Wang HS, Del Vecchio PJ, Lippe SD, and Phipps RP (1995) Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J Clin Endocrinol Metab 80:2620-2625.
338. Snow EC, Feldbush TL, and Oaks JA (1980) The role of insulin in the response of murine T lymphocytes to mitogenic stimulation in vitro. J Immunol 124:739-744.
339. Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH, and Li W (1999) Insulin-like growth factor-I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 19:3816-3828.
340. Sørensen H, Whittaker L, Hinrichsen J, Groth A, and Whittaker J (2004) Mapping of the insulin-like growth factor-II binding site of the Type I insulin-like growth factor receptor by alanine scanning mutagenesis. FEBS Lett 565:19-22.
341. Sørensen OE, Cowland JB, Theilgaard-Mönch K, Liu L, Ganz T, and Borregaard N (2003) Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 170:5583-5589.
342. Sparrow LG, McKern NM, Gorman JJ, Strike PM, Robinson CP, Bentley JD, and Ward CW (1997) The disulfide bonds in the C-terminal domains of the human insulin receptor ectodomain. J Biol Chem 272:29460-29467.
343. Street ME, de'Angelis G, Camacho-Hübner C, Giovannelli G, Ziveri MA, Bacchini PL, Bernasconi S, Sansebastiano G, and Savage MO (2003) Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 61:159-164.
344. Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, Osterborg A, et al. (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107:669-678.
345. Stuart CA, Meehan RT, Neale LS, Cintron NM, and Furlanetto RW (1991) Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes. J Clin Endocrinol Metab 72:1117-1122.
346. Taguchi T, Takenouchi H, Matsui J, Tang WR, Itagaki M, Shiozawa Y, Suzuki K, Sakaguchi S, Ktagiri YU, Takahashi T, et al. (2006) Involvement of insulin-like growth factor-I and insulin-like growth factor binding proteins in pro-B-cell development. Exp Hematol 34:508-518.
347. Tan EM (1996) Pathophysiology of antinuclear antibodies in systemic lupus erythematosus and related diseases. Adv Dent Res 10:44-46.
348. Tapson VF, Boni-Schnetzler M, Pilch PF, Center DM, and Berman JS (1988) Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor-I in vitro. J Clin Invest 82:950-957.
349. Taub DD, Tsarfaty G, Lloyd AR, Durum SK, Longo DL, and Murphy WJ (1994) Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. J Clin Invest 94:293-300.
350. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, and Martelli AM (2007) The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21:886-896.
351. Thomas AG, Holly JM, Taylor F, and Miller V (1993) Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 34:944-947.
352. Tian Z, Woody MA, Sun R, Welniak LA, Raziuddin A, Funakoshi S, Tsarfaty G, Longo DL, and Murphy WJ (1998) Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice. Stem Cells 16:193-199.
353. Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W, and Hinds CJ (1996) Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 24:1460-1466.
354. Timsit J, Savino W, Safieh B, Chanson P, Gagnerault MC, Bach JF, and Dardenne M (1992) Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. J Clin Endocrinol Metab 75:183-188.
355. Tincani A, Andreoli L, Bazzani C, Bosiso D, and Sozzani S (2007) Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 7:1-7.
356. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, et al. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857-864.
357. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, and Helman LJ (1997) The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272:30822-30827. (Pubitemid 27527522)
358. Tramontano D, Cushing GW, Moses AC, and Ingbar SH (1986) Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology 119:940-942.
359. Tramontano D, Moses AC, Picone R, and Ingbar SH (1987) Characterization and regulations of the receptor for insulin-like growth factor-I in the FRTL-5 rat thyroid follicular cell line. Endocrinology 120:785-790.
360. Tramontano D, Moses AC, and Ingbar SH (1988a) The role of adenosine 3′5′-monophosphate in the regulation of receptors for thyrotropin and insulin-like growth factor-I in the FRTL5 rat thyroid follicular cell. Endocrinology 122:133-136.
361. Tramontano D, Moses AC, Veneziani BM, and Ingbar SH (1988b) Adenosine 3′5′-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor-I in FRTL5 cells. Endocrinology 122:127-132.
362. Tsarfaty G, Longo DL, and Murphy WJ (1994) Human insulin-like growth factor-I exerts hematopoietic growth-promoting effects after in vivo administration. Exp Hematol 22:1273-1277.
363. Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, and Smith TJ (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 181:4397-4405.
364. Tu W, Cheung PT, and Lau YL (2000) Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J Immunol 165:1331-1336.
365. Twigg SM and Baxter RC (1998) Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem 273:6074-6079.
366. Uh ST, Inoue Y, King TE Jr., Chan ED, Newman LS, and Riches DW (1998) Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1626-1635. (Pubitemid 28536630)
367. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, and Altieri DC (2007) Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26:2678-2684. (Pubitemid 46663841)
368. Van Schravendijk CF, Foriers A, Van den Brande JL, and Pipeleers DG (1987) Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology 121:1784-1788. (Pubitemid 18012784)
369. Vella A, Bouatia-Naji N, Heude B, Cooper JD, Lowe CE, Petry C, Ring SM, Dunger DB, Todd JA, and Ong KK (2008) Association analysis of the IGF1 gene with childhood growth, IGF-1 concentrations and type 1 diabetes. Diabetologia 51:811-815.
370. Verschure PJ, Van Noorden CJ, Van Marle J, and Van den Berg WB (1996) Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes. Histochem J 28:835-857. (Pubitemid 27055263)
371. Vladutiu AO and Rose NR (1971) Autoimmune murine thyroiditis relation to histocompatibility (H-2) type. Science 174:1137-1139.
372. Walker JL, Zhang L, Zhou J, Woolkalis MJ, and Menko AS (2002) Role for α6 integrin during lens development: evidence for signaling through IGF-1R and ERK. Dev Dyn 223:273-284. (Pubitemid 34113405)
373. Walsh PT and O'Connor R (2000) The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis. Eur J Immunol 30:1010-1018.
374. Walsh PT, Smith LM, and O'Connor R (2002) Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology 107:461-471.
375. Wang HC and Klein JR (2001) Immune function of thyroid stimulating hormone and receptor. Crit Rev Immunol 21:323-337. (Pubitemid 34208440)
376. Wang LM, Myers MG Jr., Sun XJ, Aaronson SA, White M, and Pierce JH (1993) IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 261:1591-1594. (Pubitemid 23319604)
377. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, and Klip A (1999) Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 19:4008-4018. (Pubitemid 29241975)
378. Weightman DR, Perros P, Sherif IH, and Kendall-Taylor P (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16:251-257. (Pubitemid 24111622)
379. Werner H, Hernández-Sánchez C, Karnieli E, and Leroith D (1995) The regulation of IGF-I receptor gene expression. Int J Biochem Cell Biol 27:987-994.
380. Wetterau LA, Moore MG, Lee KW, Shim ML, and Cohen P (1999) Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 68:161-181. (Pubitemid 29501088)
381. White MF (1997) The insulin signalling system and the IRS proteins. Diabetologia 40:S2-S17.
382. Whittaker J, Groth AV, Mynarcik DC, Pluzek L, Gadsbøll VL, and Whittaker LJ (2001) Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site. J Biol Chem 276:43980-43986. (Pubitemid 37383967)
383. Whitten AE, Smith BJ, Menting JG, Margetts MB, McKern NM, Lovrecz GO, Adams TE, Richards K, Bentley JD, Trewhella J, et al. (2009) Solution structure of ectodomains of the insulin receptor family: the ectodomain of the type 1 insulin-like growth factor receptor displays asymmetry of ligand binding accompanied by limited conformational change. J Mol Biol 394:878-892
384. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, and White MF (1999) Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 23:32-40.
385. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, and Albanes D (2003) Serum insulin-like growth factor-I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63:3991-3994. (Pubitemid 36917917)
386. Wu J, Haugk K, and Plymate SR (2003) Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR. Horm Metab Res 35:751-757. (Pubitemid 38058179)
387. Wynes MW, Frankel SK, and Riches DW (2004) IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal. J Leukoc Biol 76:1019-1027.
388. Wynes MW and Riches DW (2003) Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol 171:3550-3559.
389. Xavier RJ and Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-434. (Pubitemid 47123518)
390. Xu X, Mardell C, Xian CJ, Zola H, and Read LC (1995) Expression of functional insulin-like growth factor-1 receptor on lymphoid cell subsets of rats. Immunology 85:394-399.
391. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, Morroni M, Cinti S, White MF, Herrera PL, et al. (2002) Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110:1011-1019.
392. Yamashita S, Weiss M, and Melmed S (1986) Insulin-like growth factor-I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. J Clin Endocrinol Metab 63:730-735. (Pubitemid 16050577)
393. Yang Y, Niu J, and Guo L (2002) The effects of antisense insulin-like growth factor-I receptor oligonucleotide on human cord blood lymphocytes. J Mol Endocrinol 28:207-212. (Pubitemid 34662224)
394. Yao DL, Liu X, Hudson LD, and Webster HD (1995) Insulin-like growth factor-I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 92:6190-6194.
395. Yamamoto H and Murphy LJ (1995) N-terminal truncated insulin-like growth factor- I in human urine. J Clin Endocrinol Metab 80:1179-1183.
396. Zakarija M, Jin S, and McKenzie JM (1988) Evidence supporting the identity in Graves' disease of thyroid-stimulating antibody and thyroid growth-promoting immunoglobulin G as assayed in FRTL5 cells. J Clin Invest 81:879-884. (Pubitemid 18079740)
397. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, and Goldfine ID (2008) Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem 103:624-635. (Pubitemid 351171933)
398. Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, Andrews DW, and Kornfeld H (1998) Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem 273:1144-1149.
399. Zhang Q, Tally M, Larsson O, Kennedy RT, Huang L, Hall K, and Berggren PO (1997) Insulin-like growth factor-II signaling through the insulin-like growth factor-II/mannose-6-phosphate receptor promotes exocytosis in insulin-secreting cells. Proc Natl Acad Sci USA 94:6232-6237. (Pubitemid 27270667)
400. Zhao J, Harada N, Sobue K, Katsuya H, and Okajima K (2009) Insulin-like growth factor-I reduces stress-induced gastric mucosal injury by inhibiting neutrophil activation in mice. Growth Horm IGF Res 19:136-145.
401. Zimmermann EM, Li L, Hou YT, Mohapatra NK, and Pucilowska JB (2001) Insulin-like growth factor-I and insulin-like growth factor binding protein 5 in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 280:G1022-G1029. (Pubitemid 32436041)